Age-Related Macular Degeneration Clinical Trial
Official title:
AMD Phenotype and Genotype Study (APGS)
Background:
- Age-related macular degeneration (AMD) is a disease that blurs the sharp vision needed for
activities such as reading, sewing, and driving. It affects the macula, the center of the
retina at the back of the eye, which allows a person to see fine detail. Researchers want to
collect medical histories, eye exam data, and genetic information that may be associated with
AMD. They want to compare this information with information collected from people without
AMD.
Objectives:
- To collect medical information and gene samples for researchers studying AMD.
Eligibility:
- Individuals between and 60 and 90 years of age who have AMD in at least one eye.
- Individuals between and 60 and 90 years of age who have no AMD in either eye.
Design:
- This study will involve one study visit. This study visit will last 6 to 8 hours.
- Participants will have the following tests and exams as part of their study visit:
- Full physical exam and medical history
- Full eye examination
- Laser scan of the eye
- Retina function test
- Vision sensitivity test
- Optional blood sample (for genetic study)
- No treatment will be provided as part of this study.
Objective: Late age-related macular degeneration (AMD) is the leading cause of blindness
among elderly in the United States. At present the current classification systems do not take
into consideration advances in imaging technology and genotyping and phenotyping.
Clinical centers in the US and around the world will conduct a pilot cohort study that will
bring together resources and commitment to test the feasibility of developing a new
classification scheme for AMD using imaging and visual function biomarkers, with the
potential of correlating genetic information obtained in the future. These data could
eventually help develop an understanding of the mechanisms involved in the development and
progression of AMD. A database of men and women with and without AMD will be established and
maintained. The project will recruit participants who have various stages of AMD and
controls. The pilot study will identify the feasibility of obtaining imaging and visual
function data and help identify which of these modalities should be included in a full scale
longitudinal study, as well as how frequently and at which sites they should be obtained. All
data, images and any potential biospecimens from the full scale longitudinal study will be
available to researchers worldwide to help in the development of biomarker identification and
classification development. The initiative should provide an unparalleled state-of-the-art
standardized phenotype/genotype including AMD status with information on imaging, visual
function, and biospecimen biomarkers. This study is the first phase of this initiative to
test the feasibility and logistics of defining a standard database including enhanced
phenotype and genotype data.
Study Population: This cohort study will recruit a minimum of 200 total participants with
various stages of AMD, including controls and obtain the appropriate images and measures of
visual function needed for the investigation and validation of an AMD phenotype.
Design: This cohort study is a multi-national, multi-center, observational study focused on
AMD. The study is a pilot to test the ability to create an archive of data, biological
samples (collected at other study sites), measures of visual function and ophthalmic images
collected over time from a very well clinically characterized population of participants with
a diagnosis of AMD. The database will also include a control group consisting of participants
without a diagnosis of AMD.
Outcome Measures: The design of this cohort study and the data being collected will allow
users to assess phenotypes of AMD, develop and evaluate potential markers and risk factors,
develop and evaluate an AMD classification scheme(s), and assess the progression of the
disease and investigate factors that shape it. It is not practical to anticipate all of the
potential uses of the data, or all the types of analyses that will be performed to address
user-defined questions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |